Concepedia

Publication | Open Access

Alemtuzumab CARE-MS II 5-year follow-up

DOIFull Paper Access

273

Citations

32

References

2017

Year

Alasdair Coles, Jeffrey Cohen, Edward Fox, Gavin Giovannoni, Hans‐Peter Hartung, Eva Havrdová, Sven Schippling, Krzysztof Selmaj, Anthony Traboulsee, D. A. S. Compston,
Neurology

Abstract

This study provides Class III evidence that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.

References

YearCitations

Page 1